O	0	1	A
O	2	7	phase
O	8	11	III
O	11	12	,
O	13	23	randomized
O	23	24	,
O	25	32	placebo
O	32	33	-
O	33	43	controlled
O	43	44	,
O	45	51	double
O	51	52	-
O	52	57	blind
O	58	63	trial
O	64	66	of
B-intervention	67	75	flaxseed
O	76	79	for
O	80	83	the
O	84	93	treatment
O	94	96	of
B-condition	97	100	hot
I-condition	101	108	flashes
O	108	109	:
O	111	116	North
O	117	124	Central
O	125	131	Cancer
O	132	141	Treatment
O	142	147	Group
O	148	153	N08C7
O	153	154	.

O	155	166	Preliminary
O	167	171	data
O	172	179	suggest
O	180	184	that
O	185	193	flaxseed
O	193	194	,
O	195	196	a
O	197	201	rich
O	202	208	source
O	209	211	of
O	212	219	dietary
O	220	227	lignans
O	227	228	,
O	229	232	may
O	233	235	be
O	236	237	a
O	238	249	potentially
O	250	259	effective
O	260	269	treatment
O	270	272	of
O	273	276	hot
O	277	284	flashes
O	284	285	.

O	286	287	A
O	288	293	phase
O	294	297	III
O	297	298	,
O	299	309	randomized
O	309	310	,
O	311	318	placebo
O	318	319	,
O	320	330	controlled
O	331	336	trial
O	337	340	was
O	341	350	conducted
O	351	353	to
O	354	362	evaluate
O	363	366	the
O	367	375	efficacy
O	376	378	of
O	379	387	flaxseed
O	388	390	in
O	391	399	reducing
O	400	403	hot
O	404	411	flashes
O	411	412	.

B-eligibility	413	427	Postmenopausal
I-eligibility	428	433	women
I-eligibility	434	438	with
I-eligibility	439	441	or
I-eligibility	442	449	without
I-eligibility	450	456	breast
I-eligibility	457	463	cancer
O	464	468	were
O	469	477	randomly
O	478	486	assigned
O	487	489	to
O	490	491	a
O	492	500	flaxseed
O	501	504	bar
O	505	506	(
O	506	515	providing
O	516	519	410
O	520	522	mg
O	523	525	of
O	526	533	lignans
O	533	534	)
O	535	538	for
O	539	540	6
O	541	546	weeks
O	547	553	versus
O	554	555	a
B-control	556	563	placebo
I-control	564	567	bar
O	567	568	.

O	569	581	Participants
O	582	591	completed
O	592	597	daily
O	597	598	,
O	599	610	prospective
O	610	611	,
O	612	615	hot
O	616	621	flash
O	622	629	diaries
O	630	636	during
O	637	640	the
O	641	649	baseline
O	650	654	week
O	654	655	,
O	656	659	and
O	660	664	then
O	665	668	ate
O	669	672	one
O	673	678	study
O	679	682	bar
O	683	686	per
O	687	690	day
O	691	694	for
O	695	696	6
O	697	702	weeks
O	703	708	while
O	709	718	recording
O	719	724	their
O	725	730	daily
O	731	734	hot
O	735	742	flashes
O	742	743	.

O	744	747	The
B-outcome-Measure	748	764	intraparticipant
I-outcome-Measure	765	775	difference
I-outcome-Measure	776	778	in
I-outcome-Measure	779	782	hot
I-outcome-Measure	783	788	flash
I-outcome-Measure	789	797	activity
I-outcome-Measure	798	805	between
I-outcome-Measure	806	814	baseline
I-outcome-Measure	815	818	and
I-outcome-Measure	819	822	the
I-outcome-Measure	823	827	last
I-outcome-Measure	828	837	treatment
I-outcome-Measure	838	842	week
O	843	846	was
O	847	850	the
O	851	858	primary
O	859	867	endpoint
O	867	868	.

O	869	876	Adverse
O	877	884	effects
O	885	889	were
O	890	899	evaluated
O	900	907	through
O	908	909	a
O	910	914	self
O	914	915	-
O	915	921	report
O	922	925	and
O	926	929	the
O	930	936	Common
O	937	948	Terminology
O	949	957	Criteria
O	958	968	assessment
O	968	969	.

O	970	971	A
O	972	977	total
O	978	980	of
B-total-participants	981	984	188
O	985	990	women
O	991	995	were
O	996	1004	enrolled
O	1005	1007	in
O	1008	1012	this
O	1013	1018	trial
O	1018	1019	.

O	1020	1023	The
B-outcome	1024	1028	mean
I-outcome	1029	1032	hot
I-outcome	1033	1038	flash
I-outcome	1039	1044	score
O	1045	1048	was
O	1049	1056	reduced
B-iv-cont-mean	1057	1058	4
I-iv-cont-mean	1058	1059	.
I-iv-cont-mean	1059	1060	9
O	1061	1063	in
O	1064	1067	the
O	1068	1076	flaxseed
O	1077	1082	group
O	1083	1086	and
B-cv-cont-mean	1087	1088	3
I-cv-cont-mean	1088	1089	.
I-cv-cont-mean	1089	1090	5
O	1091	1093	in
O	1094	1097	the
O	1098	1105	placebo
O	1106	1111	group
O	1112	1113	(
O	1113	1114	P
O	1115	1116	=
O	1117	1118	0
O	1118	1119	.
O	1119	1121	29
O	1121	1122	)
O	1122	1123	.

O	1124	1126	In
O	1127	1131	both
O	1132	1138	groups
O	1138	1139	,
O	1140	1148	slightly
O	1149	1153	more
O	1154	1158	than
O	1159	1160	a
O	1161	1166	third
O	1167	1169	of
O	1170	1173	the
O	1174	1179	women
O	1180	1188	received
O	1189	1190	a
O	1191	1193	50
O	1193	1194	%
B-outcome	1195	1204	reduction
I-outcome	1205	1207	in
I-outcome	1208	1213	their
I-outcome	1214	1217	hot
I-outcome	1218	1223	flash
I-outcome	1224	1229	score
O	1229	1230	.

O	1231	1235	Only
O	1236	1239	one
O	1240	1247	adverse
O	1248	1254	effect
O	1255	1258	was
O	1259	1272	significantly
O	1273	1282	different
O	1283	1290	between
O	1291	1297	groups
O	1297	1298	,
B-outcome	1299	1304	grade
I-outcome	1305	1306	1
I-outcome	1307	1315	pruritus
O	1315	1316	,
O	1317	1322	which
O	1323	1326	was
O	1327	1331	more
O	1332	1338	common
O	1339	1341	in
O	1342	1345	the
O	1346	1353	placebo
O	1354	1359	group
O	1360	1361	(
B-cv-bin-percent	1361	1362	8
I-cv-bin-percent	1362	1363	%
O	1364	1366	vs
B-iv-bin-percent	1367	1368	1
I-iv-bin-percent	1368	1369	%
O	1369	1370	)
O	1370	1371	.

O	1372	1376	Both
O	1377	1383	groups
O	1384	1392	reported
B-outcome	1393	1402	abdominal
I-outcome	1403	1413	distension
O	1413	1414	,
B-outcome	1415	1425	flatulence
O	1425	1426	,
B-outcome	1427	1435	diarrhea
O	1435	1436	,
O	1437	1440	and
B-outcome	1441	1447	nausea
O	1447	1448	.

B-outcome	1449	1458	Adherence
I-outcome	1459	1462	and
I-outcome	1463	1470	ability
I-outcome	1471	1473	to
I-outcome	1474	1480	detect
I-outcome	1481	1490	treatment
I-outcome	1491	1501	assignment
O	1502	1505	did
O	1506	1509	not
O	1510	1516	differ
O	1517	1524	between
O	1525	1531	groups
O	1531	1532	.

O	1533	1536	The
O	1537	1544	results
O	1545	1547	of
O	1548	1552	this
O	1553	1558	trial
O	1559	1561	do
O	1562	1565	not
O	1566	1573	support
O	1574	1577	the
O	1578	1581	use
O	1582	1584	of
O	1585	1588	410
O	1589	1591	mg
O	1592	1594	of
O	1595	1602	lignans
O	1603	1606	for
O	1607	1610	the
O	1611	1620	reduction
O	1621	1623	of
O	1624	1627	hot
O	1628	1635	flashes
O	1635	1636	.

O	1637	1640	The
O	1641	1645	bars
O	1646	1650	were
O	1651	1657	fairly
O	1658	1662	well
O	1663	1672	tolerated
O	1672	1673	,
O	1674	1678	with
O	1679	1683	both
O	1684	1690	groups
O	1691	1700	reporting
O	1701	1717	gastrointestinal
O	1718	1725	effects
O	1725	1726	,
O	1727	1735	probably
O	1736	1739	due
O	1740	1742	to
O	1743	1746	the
O	1747	1752	fiber
O	1753	1760	content
O	1760	1761	.
